Andrew Rice
Role in PharmNovo: Scientific advisor.
Hospital: Imperial College London.
Resumé: He received his medical degree from St. Mary’s Hospital Medical School (University of London) in 1982 and his research doctorate from St. Thomas’ Hospital Medical School (UMDS, University of London) in 1991. He underwent his specialist clinical training mainly in Oxford and at St Thomas’ Hospital. His research programme covers both laboratory and clinical research. The focus is on neuropathic pain in the context of infectious diseases, diabetic neuropathy and peripheral nerve trauma. The group is predominantly funded by grants from the Wellcome Trust, NC3Rs, European Commission and National Institute for Health Research.
In the clinical research domain: Andrew leads a programme of deep profiling studies mainly in patients with HIV neuropathy, carpal tunnel syndrome, leprosy and diabetic neuropathy. He has for many years been active in clinical trial design, conduct and interpretation and also in synthesising clinical evidence by means of meta-analyses. A recent success was his key role in the successful pre-clinical and early clinical development of the Angiotensin II type 2 receptor antagonist EMA401 as a “first in class” analgesic for neuropathic pain. He is a Councillor of the International Association for the Study of Pain (IASP) and he has held a number of positions on the Executive Committee of the International Association for the Study of Pain (IASP). He serves on the British Pain Society Council was a member of the Founding Board of the Faculty of Pain Medicine at the Royal College of Anaesthetists. He is an author of more than 160 scientific publications, many of which are in the major specialist journal in the field (PAIN).
Member of:
